BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23126027)

  • 41. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.
    Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; Cassinat B; Kiladjian JJ; Varkonyi J; Antunovic P; Westwood NB; Arno MJ; Mohamedali A; Gaken J; Kontou T; Czepulkowski BH; Twine NA; Tamaska J; Csomer J; Benedek S; Gattermann N; Zipperer E; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Jul; 20(7):1319-21. PubMed ID: 16617322
    [No Abstract]   [Full Text] [Related]  

  • 43. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
    Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
    Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
    Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
    Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
    Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
    Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
    Bojko P; Abenhardt W; Schnittger S; Haferlach T
    Onkologie; 2009 Apr; 32(4):191-5. PubMed ID: 19372714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
    Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
    [No Abstract]   [Full Text] [Related]  

  • 53. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
    De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
    Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
    [No Abstract]   [Full Text] [Related]  

  • 55. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
    Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
    Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
    Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
    Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform.
    Qian J; Lin J; Yao DM; Chen Q; Xiao GF; Ji RB; Li Y; Yang J; Qian Z
    Clin Chim Acta; 2010 Dec; 411(23-24):2097-100. PubMed ID: 20728437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.